Did You Know...
...that when IBM conducted a market study of Chester Carlson's invention in 1959, the company concluded that it would take only 5000 units of his new product to saturate the market? IBM therefore declined to be part of the new product introduction. Too bad for IBM. Carlson's invention was the xerography process, and his new product was the beginning of the Xerox Corporation. It is estimated that every day, worldwide, 3,000,000,000 copies are made!!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8057796 | Compositions and methods for the therapy and diagnosis of influenza The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection. ... | 11/15/2011 |
| 7507415 | West nile virus vaccine The invention provides chimeric flavivirus vaccines against West Nile virus and methods of using these vaccines to prevent or treat West Nile virus infection. ... | 03/24/2009 |
| 7491387 | Disinfection of foodstuffs A method of disinfection of livestock is provided. The method comprises administering at least one bacteriophage in an effective amount to said livestock to reduce the number of Campylobacter spp present in the gastro-intestinal tract of said livestock. The b... | 02/17/2009 |
| 7462360 | Alloferons—immunomodulatory peptides The invention belongs to the field of biologically active peptides specifically stimulating antiviral, antimicrobial and antitumor activity of the human and animal immune system. ... | 12/09/2008 |
| 7459163 | Infectious DNA as a vaccine against west nile and other flaviviruses A vaccine for West Nile virus that protects a subject against West Nile infection comprising an a pharmaceutically acceptable carrier and a therapeutically effective dose of an infectious agent selected from the group consisting of: a live attenuated infectious (+) ... | 12/02/2008 |
| 7459297 | Active truncated form of the RNA polymerase of flavivirus The isolation and purification of two domains from a from a flavivirus is provided. Each domain can function independently. Moreover, one domain codes for a sequence that provide polymerase activity. A process for screening possible modulators of the polymerase acti... | 12/02/2008 |
| 7459270 | Modified Vaccinia Ankara virus variant The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus... | 12/02/2008 |
| 7456018 | Human hepatoma lines, methods for obtaining same and uses thereof Human hepatoma cell lines are provided that comprises a set of cells clonally derived from a cancerous human liver cell, in which each cell of the set expresses a receptor having an affinity for binding a virus of the Flaviviridae genus and a virus of the ... | 11/25/2008 |
| 7456009 | Adenovirus formulations The invention relates to viral formulations and related pharmaceutical products for use in gene therapy and/or vaccine applications. Especially preferred viral formulations disclosed herein are liquid adenovirus formulations, which show improved stability when store... | 11/25/2008 |
| 7456008 | Modified virus comprising one or more non-native polypeptides A modified virus including one or more non-native polypeptides, and the use of such viruses in therapy, particularly in the treatment of tumours or other cancerous cells are disclosed. The polypeptides includes one or more framework moieties each containing one or m... | 11/25/2008 |
| 7455994 | Methods for producing Marburg virus proteins Using the MBGV GP, NP, and virion proteins, a method and composition for use in inducing an immune response which is protective against infection with MBGV in nonhuman primates is described. ... | 11/25/2008 |
| 7455842 | Chimeric West Nile viruses and uses thereof A chimeric West Nile live virus comprised of the NY99 and WN1415 strains and an infectious DNA recombinant construct encoding for the chimeric virus are provided, as well as immunogenic compositions and their method of use. ... | 11/25/2008 |
| 7452542 | Live attenuated coronavirus vaccines The present invention is directed live, attenuated coronavirus vaccines. The vaccine comprises a viral genome encoding a p59 protein having at mutation at a specific tyrosine residue, and may include other attenuating mutations. Such viruses show reduced growth and ... | 11/18/2008 |
| 7452541 | Hapten-carrier conjugates and uses thereof The present invention provides compositions comprising a conjugate of a hapten with a carrier in an ordered and repetitive array, and methods of making such compositions. The conjugates and compositions of the invention may comprise a variety of haptens, including h... | 11/18/2008 |
| 7449450 | Compounds, methods of screening, and in vitro and in vivo uses involving anti-apoptotic genes and anti-apoptotic gene products Novel polypeptides having anti-apoptotic activity, and methods of screening for such novel polypeptides having anti-apoptotic activity, and polynucleotides encoding such polypeptides; Compounds that regulate or modulate apoptosis and/or anti-apoptotic activity, such... | 11/11/2008 |
| 7449322 | Avian leukosis viruses and polypeptide display The invention provides methods and materials involved in displaying polypeptide sequences using viruses such as avian leukosis viruses. Specifically, the invention provides nucleic acid molecules, collections of nucleic acid molecules, polypeptides, collections of p... | 11/11/2008 |
| 7449321 | Molecules, compositions, methods and kits for applications associated with flaviviruses A method for controlling a flavivirus entry into a cell, kits for assaying the flavivirus entry into the cell, and methods of treating and preventing flaviviruses infections are disclosed, together with vaccine and pharmaceutical compositions. ... | 11/11/2008 |
| 7449188 | Recombinant oligometric protein complexes with enhanced immunogenic potential The present invention relates to a chimeric protein comprising an antigen and an oligomerisation domain. The present invention relates further to recombinant oligomeric protein complexes comprising said chimeric protein and the use thereof for the manufacture of a v... | 11/11/2008 |
| 7445889 | Methods for detecting parvovirus infections The present invention provides a method for diagnosing a subject suffering a pathological condition characterized by parvovirus infection by detecting the presence of IgE anti-Parvovirus B 19 antibodies. ... | 11/04/2008 |
| 7445787 | Methods for preventing or ameliorating West Nile encephalitis The present invention provides a safe and effective vaccine composition against West Nile virus disease. An immunogenically active component of West Nile virus or plasmid DNA, an adjuvant such as a metabolizable oil, and a pharmacologically acceptable carrier are fo... | 11/04/2008 |
| 7445785 | Infectious bronchitis virus with an altered spike gene The present invention provides a vaccine for use in the protection of poultry against infectious bronchitis comprising an attenuated infectious bronchitis virus (IBV) and a pharmaceutical acceptable carrier or diluent, characterized in that the attenuated IBV compri... | 11/04/2008 |
| 7442498 | Method of examining specimen and specimen container to be used in the examination method A method of immunologically examining a specimen which comprises attaching a cap having a filter impregnated with a labeled antibody enclosed therein to a container body containing a diluted liquid specimen, pouring the diluted liquid specimen from the container int... | 10/28/2008 |
| 7442377 | Protective antigen of epstein barr virus The present invention relates to the identification of a subunit vaccine to prevent or treat infection of Epstein Barr Virus. In particular, EBNA-1 was identified as a vaccine antigen. In a specific embodiment, a purified protein corresponding to EBNA-1 elicited a s... | 10/28/2008 |
| 7439347 | Hepatitis C virus non-structural NS3/4A fusion gene Disclosed herein is the discovery of a novel hepatitis C virus (HCV) isolated from a human patient. Embodiments of the invention include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nuclei... | 10/21/2008 |
| 7439015 | Methods for detecting DNA viruses A DNA virus in a sample is detected by contacting the sample with host cells that have been transiently transfected with a reporter sequence under the control of a virus-specific promoter, and then detecting the reporter. ... | 10/21/2008 |
| 7435538 | High throughput screening method of drug for physiologically active protein The present invention is intended to provide a safe and quick means for screening a drug to a bioactive protein, in particular, an inhibitor, using a cell-free protein synthesis system with the use of a wheat embryo extract solution. The present inventors have stren... | 10/14/2008 |
| 7432101 | Production of poxviruses with adherent or non adherent avian cell lines The present invention relates to a method for replicating pox viruses such as vaccinia virus comprising the steps of inoculating avian embryonic stem cells with viral particles and culturing said cells in a basal medium until cells lysis occurs and newly produced vi... | 10/07/2008 |
| 7432046 | Methods for the determination of antibody IgG avidity The present invention relates to methods of determining anti-infectious agent IgG avidity, for example, human anti-cytomegalovirus and human anti-toxoplasma IgG avidity, using a competitive assay format. ... | 10/07/2008 |
| 7431930 | Infectious bursal disease virus (IBDV) mutant expressing virus neutralising epitopes specific for classic-and variant IBDV strains The present invention provides a classic IBDV mutant that additionally comprises virus neutralising epitopes 67 (specific for variant-E IBDV). ... | 10/07/2008 |
| 7431929 | Use of vaccinia virus deleted for the E3L gene as a vaccine vector The present invention relates to vaccines having an increased level of safety comprising recombinant vaccinia viruses containing an inactivated E3L region. The invention also relates to methods for stimulating a protective immune response in an immunized host using ... | 10/07/2008 |
| 7427658 | Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1, VP2 and VP3 or sequences of that virus coding therefor The coding information for three putative chicken anemia virus proteins (VP1, VP2, VP3) was inserted into a baculovirus vector and expressed in insect cells. Only lysates of insect cells which have synthesized equivalent amounts of all three recombinant CAV proteins... | 09/23/2008 |
| 7425437 | Vaccines against West Nile Virus The present invention relates to novel vaccines containing (whole-inactivated) West Nile Viruses and/or West Nile viral proteins derived therefrom, produced on human cells, wherein the human cells comprise a sequence encoding at least one early region-1 (E1) gene pr... | 09/16/2008 |
| 7419674 | Alpha virus-based cytomegalovirus vaccines The present invention provides methods and compositions comprising a population of alphavirus replicon particles comprising alphavirus replicon RNAs, wherein a first replicon RNA comprises nucleic acid encoding cytomegalovirus pp65 and IE1 protein or immunogenic fra... | 09/02/2008 |
| 7419816 | Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies and gene therapy in the CNS A mutant virus contains a mutation at a phosphorylation site in one or more viral proteins, which attenuates the virus, and an improved vaccine composition. The invention also relates to methods of inducing an immune response, and protecting mammals from infection b... | 09/02/2008 |
| 7417126 | PRO246 antibodies The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of ... | 08/26/2008 |
| 7416840 | Replication of hepatitis C virus in non-hepatic epithelial and mouse hepatic cells Cells and cell lines which replicate HCV of non-hepatic human and non human origin are disclosed. Also provided are methods of using such cells and cell lines to identify anti-HCV agents for the treatment of HCV infection. ... | 08/26/2008 |
| 7410646 | Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine Immunologically active polypeptides with no or reduced toxicity useful for the preparation of an antipertussis vaccine. Method for the preparation of said polypeptides which comprises, cultivating a microorganism transformed with a hybrid plasmid including the gene/... | 08/12/2008 |
| 7393677 | Avidin-pseudotyped viral vectors and their use The present invention pertains to an avidin-pseudotyped virus, and especially baculovirus, useful for delivery of foreign genes etc. The present invention also pertains to vectors comprising respective cassettes for pseudotyping, mammalian gene expression and insect... | 07/01/2008 |
| 7390888 | Dendritic cell potentiation A molecule capable of potentiating immune responses is described, as well as methods for using the molecule to enhance immune responses and enhance dendritic cell function. Also described are compositions containing the molecule and methods for using the composition... | 06/24/2008 |
| 7385039 | Methods and compositions for regulating imidazoline receptors The present invention relates to methods and compositions for regulating the activity of imidazoline receptors. In particular, the invention relates to pharmaceutical compositions comprising imidazoleacetic acid-ribotide (IAA-RP), imidazoleacetic acid-riboside (IAA-... | 06/10/2008 |
